TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells

Toll-like receptor 3 (TLR3) agonists have been extensively used as adjuvants for anticancer vaccines. However, their immunostimulatory effects and precise mechanisms of action in the presence of antineoplastic monoclonal antibodies (mAbs) have not yet been evaluated. We investigated the effect of TL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ming Lim, Chwee, Stephenson, Ryan, Salazar, Andres M, Ferris, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716757/
https://www.ncbi.nlm.nih.gov/pubmed/23894722
http://dx.doi.org/10.4161/onci.24677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716757/
https://www.ncbi.nlm.nih.gov/pubmed/23894722
http://dx.doi.org/10.4161/onci.24677

Ejemplares similares